Phase II trial of carboplatin/docetaxel in patients with resected NSCLC

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 1

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Respirology

ISSN

2218-6255

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Respirol. Mar 28, 2014; 4(1): 1-7
Published online Mar 28, 2014. doi: 10.5320/wjr.v4.i1.1

Table 2 Drug delivery n (%)

Number of cycles delivered
1	61 (100)
2	58 (95)
3	51 (84)
Total	170
Median	3
Number of patients who required dose reduction of
CBDCA	43 (70)
DTX	43 (70)
Mean dose intensity (% planned)
CBDCA	4.3 AUC (86.7)
DTX	51.8 mg/m² (86.3)
Median dose intensity (% planned)
CBDCA	4.3 AUC (86.7)
DTX	53.3 mg/m² (88.8)

CBDCA: Carboplatin; DTX: Docetaxel; AUC: Area under the curve.

Citation: Uramoto H, Nakanishi R, Uchiyama A, Inoue M, Sugaya M, Iwata T, Ebi N, Hanagiri T, Tanaka F. Phase II trial of carboplatin/docetaxel in patients with resected NSCLC. World J Respirol 2014; 4(1): 1-7
URL: https://www.wjgnet.com/2218-6255/full/v4/i1/1.htm
DOI: https://dx.doi.org/10.5320/wjr.v4.i1.1

Uramoto H, Nakanishi R, Uchiyama A, Inoue M, Sugaya M, Iwata T, Ebi N, Hanagiri T, Tanaka F. Phase II trial of carboplatin/docetaxel in patients with resected NSCLC. World J Respirol 2014; 4(1): 1-7 [DOI: 10.5320/wjr.v4.i1.1]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.